Pd43-03 Elevated Skin Sympathetic Nerve Activity as a Predictor of Oral Monotherapy Refractoriness in Overactive Bladder

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Overactive Bladder I (PD43)1 May 2024PD43-03 ELEVATED SKIN SYMPATHETIC NERVE ACTIVITY AS A PREDICTOR OF ORAL MONOTHERAPY REFRACTORINESS IN OVERACTIVE BLADDER Yu-Chen Chen, Hao-Wei Chen, Wei-Chung Tsai, and Yung-Shun Juan Yu-Chen ChenYu-Chen Chen , Hao-Wei ChenHao-Wei Chen , Wei-Chung TsaiWei-Chung Tsai , and Yung-Shun JuanYung-Shun Juan View All Author Informationhttps://doi.org/10.1097/01.JU.0001009568.19060.25.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Identifying predictors for unsatisfactory outcomes of oral monotherapy is crucial in the management of overactive bladder (OAB). We recently published that the significantly elevated skin sympathetic nerve activity (SKNA) was found in patients OAB compared to controls, suggesting its potential as a diagnostic biomarker for OAB. This study aims to investigate the association between heightened SKNA levels and OAB patients who do not respond to monotherapy. We hypothesize that elevated sympathetic nerve activity may contribute to treatment resistance and provide insights into potential therapeutic targets for non-responders. METHODS: A prospective sample of 55 newly diagnosed female patients with idiopathic OAB, eligible for OAB drug therapy, was included. Before treatment, autonomic function was evaluated using neuECG, which simultaneously analyzed skin sympathetic nerve activity and electrocardiogram in the morning. All patients underwent urodynamic studies before initiating treatment. Initial monotherapy was administered for the first 4 weeks, and non-responders were defined as patients who did not achieve satisfactory symptom relief and subsequently required combination therapy or third-line treatment after the 4-week period. RESULTS: Baseline characteristics and urodynamic parameters did not show significant differences between responders and non-responders to monotherapy. However, non-responders exhibited significantly higher baseline average SKNA (aSKNA) (p=0.001), higher recovery aSKNA (p=0.007), and a lower stress/baseline ratio of aSKNA (p=0.029) (Table 1). There were no significant differences in heart rate variability-related parameters between the two groups. CONCLUSIONS: In idiopathic OAB patients resistant to oral monotherapy, pre-treatment aSKNA exhibits a significant increase. The baseline aSKNA emerges as a promising candidate for predicting treatment outcomes in OAB. In individuals with elevated aSKNA, employing more proactive treatment strategies and closely monitoring therapeutic results may be considered. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e899 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Yu-Chen Chen More articles by this author Hao-Wei Chen More articles by this author Wei-Chung Tsai More articles by this author Yung-Shun Juan More articles by this author Expand All Advertisement PDF downloadLoading ...